Skip to main content
. 2019 May 3;8(2):171–184. doi: 10.1007/s40121-019-0247-0

Table 2.

As-treated outcomes for all indications

UMMC (%) VAMHCS (%) Total (%)
30 days
 Follow-up 7 (58) 14 (88) 21 (75)
 Cure 5 (71) 10 (71) 15 (71)
 Failure 2 (29) 4 (29) 6 (29)
Adverse eventsa
 Renal 1 (14) 1 (7) 2 (10)
 Pruritus 1 (14) 0 (0) 1 (5)

aOf total patients evaluable at day 30